A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics
and preliminary efficacy of the investigational drug PLX2853 in subjects with Relapsed or
Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome